CCO Treatment Updates
HBV Providers’ Choice in Prime Time: Addressing Issues of Patient Populations, Resistance, Individualized Treatment, Management, and Efficacy
Interactive Virtual Presentations
HBV Patient Populations: Treating Hepatitis B in the Setting of Pregnancy
|
Program Director: Nezam H. Afdhal, MD, FRCPI
|
|
Join Heiner Wedemeyer, MD, as he reviews HBV infection management in the setting of pregnancy and potential pregnancy.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss factors involved in deciding whether to treat hepatitis B in candidates for therapy wanting to get pregnant
- Describe strategies for treatment of hepatitis B in pregnant women and the potential effects of drugs on the developing fetus
- Review issues surrounding vertical transmission of hepatitis B virus, including strategies for reducing transmission and nursing issues
|
HBV Patient Populations: Treating HBV in the Setting of Pregnancy
 |
|
Download and review key data selected by Heiner Wedemeyer, MD, on HBV infection management in the setting of pregnancy and potential pregnancy. Use the slides in your own presentations!
Format: Microsoft PowerPoint (.ppt) |
File size: 482 KB
|
Efficacy, Resistance, and Durability
|
Program Director: Nezam H. Afdhal, MD, FRCPI
- Stephen Locarnini, MD, PhD, FRC (Path)
|
|
|
Join Stephen Locarnini, MD, PhD, FRC (Path), as he discusses current concepts on how to best avoid antiviral resistance to initial HBV therapies.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize recent data on the differing efficacy of anti-HBV agents and their implications for individualizing HBV treatment
- Identify factors affecting the development of resistance to antiviral agents used to treat HBV infection
- Explain treatment strategies to minimize or avoid the development of resistance in hepatitis B patients
|
Efficacy, Resistance, and Durability
 |
|
Download and review key data selected by Stephen Locarnini, MD, PhD, FRC (Path), on the importance of initial HBV regimen efficacy in avoiding resistance and achieving durable responses.
Format: Microsoft PowerPoint (.ppt) |
File size: 593 KB
|
Management of Suboptimal Response
|
Program Director: Nezam H. Afdhal, MD, FRCPI
|
|
Join Ching-Lung Lai, MD, as he reviews strategies to identify and manage incomplete response in HBV-infected patients receiving treatment with oral antiviral therapies.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recount clinical data on the role of early on-treatment HBV DNA levels in predicting long-term response of HBV-infected patients to therapy with oral antiviral agents
- Identify optimized strategies to detect and manage early nonresponse to oral antiviral agents
- Discuss key factors to consider when selecting oral agents for switch or add-on approaches in patients with evidence of resistance to their current regimen
|
Management of Suboptimal Response
 |
|
Download and review key data selected by Ching-Lung Lai, MD, on managing HBV patients with suboptimal responses, including consideration of definitions of response and management of partial response.
Format: Microsoft PowerPoint (.ppt) |
File size: 490 KB
|
Disclaimer: The materials published on the Clinical Care Options
Web site reflect the views of the reviewers or authors of the
CCO
material, not those of Clinical Care Options, LLC, the CME provider,
or the companies providing educational grants. The materials may
discuss uses and dosages for therapeutic products that have not been
approved by the United States Food and Drug Administration. A qualified
healthcare professional should be consulted before using any therapeutic
product discussed. Readers should verify all information and data before
treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|